ImmunoGen Announces Conference Call to Discuss Its 2017 Operating Results

January 26, 2018 8:00 AM

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 9, 2018 to discuss its 2017 operating results. Management also will provide a brief update on the business.

Conference Call InformationTo access the live call by phone, dial 719-325-4917; the conference ID is 5734226. The call may also be accessed through the Investors section of the Company’s website, Following the webcast, a replay of the call will be available at the same location through February 23, 2018.

About ImmunoGen, Inc.ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. The Company’s lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in a Phase 1b/2 trial in combination regimens for earlier-stage disease. ImmunoGen has three additional clinical-stage product candidates, two of which are being developed in collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC technology is also used in Roche's marketed product, Kadcyla®, and in programs in development by Amgen, Bayer, Biotest, CytomX, Debiopharm, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at

Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.

For Investors

ImmunoGen, Inc.

Sarah Kiely, 781-895-0600


For Media

ImmunoGen, Inc.

Courtney O'Konek, 781-895-0600


Robert Stanislaro

FTI Consulting, Inc., 212-850-5657

Source: ImmunoGen, Inc.


Press Releases